From Pasqualotto et al 2009
Commenting from the University of Manchester, Professor David Denning, who also works at the University Hospital of South Manchester, said: “We were surprised by the number of patients with ABPA, and by the lack of community based studies done. Our National Aspergillosis Centre treats hundreds of these patients each year, generally with major improvement, and so a conscious program to seek out ABPA from all asthmatics is required.”
Denning DW, Pleuvry A, Cole DC. Global burden of ABPA in adults with asthma and its complication chronic pulmonary aspergillosis. Med Mycol 2013;51:361-70.
To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, Boulet LP. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204
RCTs A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis Stevens DA, Schwartz HJ, Lee JY, Moskovitz BL, Jerome DC, Catanzaro A, Bamberger DM, Weinmann AJ, Tuazon CU, Judson MA, Platts-Mills TA, DeGraff AC Jr. . N Engl J Med. 2000;342:756-62.
Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. Wark PA, Hensley MJ, Saltos N, Boyle MJ, Toneguzzi RC, Epid GD, Simpson JL, McElduff P, Gibson PG. J Allergy Clin Immunol. 2003;111:952-7.
Alternative antifungal therapy Chishimba L, Niven RM, Cooley J, Denning DW. Voriconazole and posaconazole for ABPA and SAFS – clinical benefit and reduction in asthma severity. J Asthma 2012;49:423-33.